Table 6.
Liver volumetry by chemotherapy group in patients who underwent portal vein embolization (PVE) with and without bevacizumab (bev)
| Bev (n = 47) | Non-bev (n = 42) | P-value | |
|---|---|---|---|
| Total liver volume, cm3, median (range) | |||
| Pre-PVE | 1588 (1444–2000) | 1685 (1377–2073) | 0.617 |
| Post-PVE | 1635 (1415–2037) | 1766 (1385–2135) | 0.581 |
| Future liver remnant, %, median (range) | |||
| Pre-PVE | 20.8 (15.1–23.8) | 21.3 (14.9–26.4) | 0.373 |
| Post-PVE | 28.8 (21.9–34.5) | 28.7 (24.8–35.7) | 0.825 |
| Degree of hypertrophy | 7.5 (3.4–11.2) | 5.1 (1.0–12.5) | 0.127 |